Royalty portfolio Ligand’s extensive diversified royalty holdings across 200+ development and commercial assets present multiple cross-sell opportunities with biopharma partners seeking non-dilutive funding and long-term monetization options.

Capital raising Recent large-scale financing moves, including a 700 million zero-coupon convertible noted offering, indicate readiness for strategic partnerships and potential co-financing of high-value programs through structured equity or debt-enabled royalty deals.

Technology license Proprietary capabilities Captisol and NITRICIL offer adjacent collaboration avenues for partners needing formulation and drug delivery enhancements, enabling bundled deals that combine royalties with technology licensing.

Clinical expansion Ligand’s growth strategy centers on late-stage programs; sales teams can target high-potential biopharma assets near commercialization, aligning licensing terms with anticipated earnings streams and risk-adjusted returns.

Investor engagement Upcoming investor events and disclosed revenue trajectories create openings for outreach to capital markets teams and DCF-focused stakeholders, positioning Ligand as a partner for scalable royalty financings and strategic partnerships.